Valo SPAC Presentation Deck
Valo's scalable acceleration model is designed to build a 'supply chain' of
programs - aspiration to become the standard drug development platform
Cross-program active learning benefits internal and external programs
INTERNAL SUPPLY CHAIN
OF PROGRAMS
CURRENT
FOCUS THERAPEUTIC AREAS:
ONCOLOGY
Multiple Drug Candidates expected in 2021¹
PROGRAMS/INSIGHTS
CARDIOVASCULAR-METABOLIC-RENAL
First clinical program launch expected in 2021¹
DATA
NEURODEGENERATIVE
Multiple novel preclinical programs expected
in 2021¹
OPAL ACCELERATION FLYWHEEL
DATA
DRUG
DEVELOPMENT
Phase III Phase II
BIOLOGICAL DISCOVERY
Target
Discovery
RWE
Diagnosis
Opal
PLATFORM
Phasel
Preclinical
Target ID
Lead Opt
PROGRAMS/INSIGHTS
THERAPEUTIC DESIGN
Both internal & external programs benefit from Opal's scale
DATA
COMPUTE
10000
EXTERNAL SUPPLY CHAIN
OF PROGRAMS
EMERGING
EMERGING ECOSYSTEM:
PARTNERSHIPS
SOFTWARE
SOLUTIONS
EARLY DISCOVERY
END-TO-END
PRECLINICAL
CLINICAL
MANUFACTURING
The self-reinforcing nature of Opal's flywheel is designed to enable increasing utility with and at scale
Valo [1] Reflects management's 2021 goals
2Q21
32View entire presentation